engleski

Use of LMW heparin in pregnant patients with antiphospholipid syndrome - a prospective study

Objective. Heparin therapy is today very well established in pregnant women with antiphospholipid syndrome. Study design. This study was prospective clinical trial, and included 24 pregnant women with antiphospholipid syndrome in whom low-molecular heparin (Clivarin) was introduced in dose of 2 x 1750 IU/day, s.c. Therapy started from as early as sonogram demonstrated a live embryo and continued throughout the pregnancy until the end of puerperium. Results. All pregnancies terminated favourably at 38.4ą1.6 (meanąSD) weeks of gestation, with planned cesarean section in 13 cases and vaginal delivery 11. The newborns had mean birthweight of 3106.5ą775.7 grams and under 10th percentile were born 4 infants or 16.7%. Coagulation parameters changed during heparin therapy: fibrinogen values were increased significantly in comparison to its initial values (F=12.4; p<0.05); fibrinolysis was slowed down (F=17; p<0.05). The statistically significant correlation was found between coagulation parameters and newborns birthweight: in cases with slower fibrinolysis and newborns born from such pregnancies were significantly heavier. Conclusion. LMWH administered alone using dosages and timing described here was effective in achieving the delivery of healthy newborns.

Heparin; pregnancy; antiphospholipid syndrome

nije evidentirano